Novo Nordisk A/S (BKK:NOVOB80)
Thailand · Delayed Price · Currency is THB | Market Cap | 7.27T -26.9% |
| Revenue (ttm) | 1.65T +8.1% |
| Net Income | 614.02B +16.6% |
| EPS | 138.01 +16.8% |
| Shares Out | n/a |
| PE Ratio | 11.84 |
| Forward PE | 16.00 |
| Dividend | 0.04 (2.53%) |
| Ex-Dividend Date | Mar 27, 2026 |
| Volume | 1,460,113 |
| Open | 1.610 |
| Previous Close | 1.590 |
| Day's Range | 1.610 - 1.660 |
| 52-Week Range | 1.120 - 2.360 |
| Beta | 0.36 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 5, 2026 |
About Novo Nordisk
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Pl... [Read more]
Financial Performance
In 2025, Novo Nordisk's revenue was 309.06 billion, an increase of 6.43% compared to the previous year's 290.40 billion. Earnings were 102.43 billion, an increase of 1.43%.
Financial numbers in DKK Financial StatementsNews
Why Is Novo Nordisk Suing Eli Lilly, and What Does it Mean for Investors?
Eli Lilly's ads don't account for a new, higher dose of Novo Nordisk's Wegovy. Lilly has been winning the race to dominate the GLP-1 drug market.
Novo Nordisk Pursues Injunction to Block Eli Lilly’s (LLY) Advertisements
The two companies dominate the market for obesity medications.
As Lilly and Novo Clash in Court, Wall Street Is Eyeing This Bigger Prize
The legal battle between Novo Nordisk and Eli Lilly is escalating, but analysts are more focused on developments in the lab.
Novo Nordisk Seeks Injunction Against Eli Lilly in Dispute Over Weight-Loss Ads
Friday's preliminary injunction request escalates legal proceedings initiated earlier this week.
Novo Nordisk seeks preliminary injunction against Lilly weight-loss ads
Novo Nordisk said on Friday it is seeking a preliminary U.S. court injunction to immediately block obesity and diabetes drug advertisements by Eli Lilly , in a further escalation of the rivalry bet...
Crux Collaborates with Novo Nordisk to Offer Access to Wegovy® and Other Obesity Management Medications
MCLEAN, Va.--(BUSINESS WIRE)--Crux, a benefits operating system that connects employers, pharmaceutical manufacturers, and benefit solution providers, today announced a collaboration with global healt...
Weight loss drugs linked to increase risk of hair loss
Weight loss drugs such as Mounjaro, Ozempic and Wegovy are linked to an increased risk of hair loss, according to researchers.
Hair loss with GLP-1 drugs is rare, but real, studies find
The risk of hair loss in patients taking GLP-1 drugs for obesity or diabetes, while low, is higher than with other diabetes drugs, new studies suggest.
Many US patients opt for obesity drug injections, defying some expectations
Many patients have opted for injectable forms of the wildly popular GLP-1 obesity medications through a pilot program of the U.S. government's Medicare health insurance program for Americans aged 65 ...
"Deceptive Advertising!" Claims Novo Nordisk in Explosive New GLP-1 Lawsuit Against Eli Lilly.
Novo Nordisk has sued rival GLP-1 drugmaker Eli Lilly in federal court, alleging misleading advertising. Novo alleges that Lilly's ads compare a lower dosage of its weight loss drug Wegovy to the high...
Novo Nordisk Sues Eli Lilly Over Weight-Loss Drug Advertising
Novo Nordisk alleges Eli Lilly falsely advertised Zepbound and Mounjaro by claiming the drugs outperform Wegovy and Ozempic.
Novo Sues Rival Lilly Over Weight-Loss Ads
Novo Nordisk A/S is suing rival drugmaker Eli Lilly & Co. for showing what it calls are misleading ads about obesity drugs in the US. Novo says Lilly is using outdated information when comparing Novo'...
Eli Lilly (LLY) Hit with Lawsuit by Rival Novo Nordisk Over Weight-Loss Drug Ads
Competition between the drug makers is intensifying.
Novo Nordisk Sues GLP-1 Rival Eli Lilly For Misleading Advertising
Ozempic drugmaker Novo Nordisk sued rival GLP-1 manufacturer Eli Lilly in federal court Tuesday, accusing the company of using “intentionally selected outdated studies” to curate allegedly misleading ...
Novo Nordisk's Dividend Story Is Changing -- Here's What Investors Are Missing
Novo Nordisk is one of the leading makers of GLP-1 weight-loss drugs. The stock has a well-above-market yield that is also well above its industry peers.
Novo Nordisk sues Eli Lilly over weight-loss drug advertising claims
Novo Nordisk has filed a lawsuit against Eli Lilly (LLY) in a US federal court, accusing its rival of running false and misleading advertising campaigns for its blockbuster diabetes and weight-loss dr...
Novo Nordisk sues Eli Lilly over ads comparing GLP-1 medications
The drugmaker says Lilly isn't including the most up-to-date clinical information about its drugs
Novo Nordisk filed a lawsuit against rival Eli Lilly accusing it of using outdated studies to promote its GLP-1 drugs
The maker of Ozempic and Wegovy says its competitor is misleading consumers by citing outdated weight-loss data in advertisements.
Novo Nordisk files lawsuit against ‘misleading’ GLP-1 ads from Eli Lilly
Novo Nordisk (NVO) announced that it has filed a lawsuit against Eli Lilly (LLY) in the United States District Court for the District of New Jersey for what it calls…
Novo Nordisk suing Eli Lilly over weight-loss ads, Bloomberg reports
Novo Nordisk (NVO) said in U.S. federal court that it is suing Eli Lilly (LLY), claiming that its competitor’s advertising for its obesity shot Zepbound and diabetes injection Mounjaro is…
Novo Nordisk says it is suing Eli Lilly, accusing it of false advertising
Novo Nordisk said on Tuesday it was suing rival Eli Lilly in U.S. federal court, accusing the U.S. drugmaker of false advertising in claiming its weight-loss medicines outperform Novo's drugs.
Novo Nordisk sues Eli Lilly, alleging misleading GLP-1 advertising
Novo Nordisk filed a lawsuit against Eli Lilly, alleging that its advertising campaigns for its blockbuster obesity and diabetes drugs are designed to mislead consumers about their superior efficacy r...
Novo Nordisk price target raised to DKK 330 from DKK 290 at Citi
Citi analyst Graham Parry raised the firm’s price target on Novo Nordisk (NVO) to DKK 330 from DKK 290 and keeps a Neutral rating on the shares. Published first on…
One in Every Five U.S. Homes Using GLP-1s: What it Means for Consumer Trends
MichaelAaron Flicker examines the growing impact of GLP-1 medications on consumer behavior, noting that roughly one in five American households has someone using a GLP-1 drug. He explains how that tre...
Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics Just Started Testing a Weight Loss Drug That Goes Beyond GLP-1
Viking Therapeutics just launched its next-gen weight loss program. Novo Nordisk and Eli Lilly are already deep into the development process with comparable programs.